ResMed Inc. announced that it has acquired Laboratoires Narval. Based inFrance, Laboratoires Narval manufactures and distributes the Narval O.R.M.(TM), a mandibular repositioning device (MRD) that offers a solution to patients for snoring and obstructive sleep apnea (OSA), especially for those with mild OSA. With this acquisition, ResMed adds another therapy to supplement its existing positive airway pressure-based solutions. ResMed plans to commercialize this device in selected European markets.
"Obstructive sleep apnea is a serious disease that, left untreated, can have significant long-term impacts on the cardiovascular system, as well as impacts on other serious and chronic health issues," saidMichael Farrell, Senior Vice President of the Sleep Business Unit, ResMed. "The gold-standard therapy for obstructive sleep apnea is continuous positive airway pressure (CPAP) therapy. ResMed will now be able to provide an alternative solution for patients with mild obstructive sleep apnea as well as those with snoring. In addition, inFrance, there is reimbursement for MRD use as a second line treatment for severe OSA for those who are non-compliant on or refuse CPAP. We have found a good match in Narval as we both strive for clinical excellence and quality therapy solutions through market-leading innovation, education and service."